ESR1 and breast carcinoma: We found that if ER(-)/PR(+) type breast cancer is combined with HER-2(+), the clinical prognosis is improved compared with HER-2(-), suggesting that these patients have poor effect of endocrine therapy, but if HER-2(+), they may benefit from anti-HER2 treatment.